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March 10, 2009:898–903enotype) polymorphism association with variable clopidogrel re-
ponse has been validated in both healthy and acute coronary
yndrome individuals (3). The association of platelet glycoproteins
IIa and P2Y12 receptor polymorphisms with clopidogrel variable
esponse has not been confirmed in previous studies (4), and it should
lso be examined in the study by Ang et al. (1).
Finally, other mechanisms, such as cellular factors (accelerated
latelet turnover, reduced CYP3A metabolic activity, increased
DP exposure, up-regulation of P2Y pathways), or clinical factors
noncompliance, underdosing, poor absorption) may cause subop-
imal clopidogrel response.
This interesting study by Ang et al. (1) sheds some light on
echanisms underlying reduced response of platelets to the anti-
ggregatory effect of clopidogrel. Although the limited number of
atients with lower inhibition of platelet reactivity by clopidogrel
akes the findings exploratory, further studies with a larger cohort
f patients are needed to elucidate the multiple mechanisms
nvolving clopidogrel response.
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eply
e appreciate the comments by Dr. Siasos and colleagues in
esponse to our recent study published in the Journal (1). We agree
hat many factors are associated with variable platelet reactivity
esponse to clopidogrel, including drug absorption, generation of
ctive drug metabolites, cytochrome P450 isoenzyme variants,
rug–drug interactions, and P2Y12 receptor polymorphisms. In
articular, significant efforts have been directed at clarifying the
ole of hepatic cytochrome P450 isoenzymes, including CYP3A4,
YP3A5, and CYP2C19 polymorphisms. Although there are
onflicting data, a significant role of CYP3A4*1B or CYP3A5*3
olymorphisms in accounting for lower platelet inhibition (PI)
ith clopidogrel seems unlikely (2). However, CYP2C19 geno-
yping allows identification of 90% of poor clopidogrel metabo-izers (3), and carriers of the CYP2C19*2 mutant allele seem to
ave an attenuated PI response when presenting with an acute
oronary syndrome (ACS) or undergoing an elective percutaneous
oronary intervention (2,4).
The goal of our study was to determine the role of clinical and
iochemical factors known to affect platelet reactivity on the PI
ttained with clopidogrel in patients with cardiovascular disease
1). Elevated serum fibrinogen, diabetes mellitus, and higher body
ass index were associated with a lower PI. A significant interac-
ion was also observed between diabetes and elevated fibrinogen,
ccounting for at least one mechanism for the poor response of
iabetics to clopidogrel. As acknowledged in the Study Limita-
ions section of our article (1), we did not assess patients for genetic
olymorphisms. In patients with ACS treated with clopidogrel,
rere et al. (2) found a significant association between being a
arrier of the CYP2C19*2 mutant allele and higher platelet
eactivity. Nevertheless, higher body mass index remained inde-
endently associated with higher post-treatment platelet reactivity.
alek et al. (5) have shown that ACS patients with polymor-
hisms for both the P2Y12 platelet receptor and CYP2C19 are at
n increased risk of excess platelet activity after clopidogrel
reatment, and have a higher risk of ischemic cardiovascular events.
owever, no known data suggest that the role of the clinical and
iochemical markers that we have identified would be altered in
he presence or absence of a P2Y12 receptor or CYP2C19
olymorphism. Future studies should expand on our findings by
etermining P2Y12 and glycoprotein IIIa platelet cell-surface
eceptor, and CYP450 isoenzyme genotypes, and evaluating their
nteractions with the clinical and biochemical markers of poor
latelet inhibition with clopidogrel.
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